Kytopen
company
About
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
- 11 - 50
Details
- Last Funding Type
- Non-Equity Assistant
- Industries
- Biotechnology,Genetics,Health Care,Life Science
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$31.21M
Kytopen has raised a total of
$31.21M
in funding over 2 rounds. Their latest funding was raised on
Sep 28, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 28, 2021 | Series A | $30M | 1 | — | — | Detail |
| Dec 8, 2020 | Angel | $195K | 1 | — | — | Detail |
| Mar 1, 2019 | Grant | $798.46K | 1 |
National Science Foundation
|
— | Detail |
| Feb 4, 2019 | Non-Equity Assistant | — | 1 | — | — | Detail |
| Dec 21, 2017 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Kytopen is funded by 3 investors.
National Science Foundation
and TBD Angels
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
TBD Angels
|
— | Series A |
Merck
|
— | Non-Equity Assistant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
